The biotechnology stocks sector means
all the companies that bring together scientists on applications
technological in pharmacy, chemistry and other…
This is one of the most speculative areas on
the stock market, because most of the time the value of the stock is
the potential for successful treatment rather than a turnover already
performed.
Capitelia follows in particular this sector in
a measure specific to the wishes of the clientele (according to the risk profile
accepted). In this article, we will introduce you to 3 companies that
hold our attention.
Onxeo: “Onxeo is a clinical biotechnology company that designs and develops new cancer drugs targeting the DNA repair functions of tumors.
Our approach is based on unparalleled mechanisms of action that disrupt the response to damage to tumor DNA. We focus on the development – from translational research to proof of concept in humans – of « first-in-class » or disruptive compounds to treat cancers for which the unmet medical needs remain considerable. «
Biotechnology company with a high potential / risk ratio, with many treatments and research in progress, patents and potential drugs.
Limited impact of Coronavirus on society.
The objective is around 1.5 € (against 0.5 € value at 31/03) taking into account the financial situation and at the research stage.
ABIONYX PHARMA “ABIONYX Pharma is a new generation biotechnology company dedicated to the discovery and development of innovative therapies for patients without existing or effective treatment.
Based on its current resources, ABIONYX plans to develop its activities with the existing assets inherited from Cerenis. ABIONYX is also exploring partnership activities. «
Very large product portfolio under test, and growing product marketing allow us to expect a sharp rise in share prices.
Cerenis has a multitude of molecules in the research and testing stages, which will be marketable if tests on humans prove positive, in which case the price could then be doubled.
Cerenis has just acquired the assets of LYPRO and therefore got its hands on nanoparticle technology which will make it possible to transport in HDL particles of cerenis several drugs, even in high doses, to treat several cancers and several autoimmune diseases. This technology would greatly reduce the side effects of drugs and their intoxication and would also deliver large doses to cancer cells while protecting healthy cells.
Cerenis is cited among the companies with the most potential for remedies for rare diseases and without treatment.
A change of director took place in December 2018 who is now « Richard Pasternak » a great biopharmacy researcher and former vice-president of Merck (pharmaceutical company with a capitalization of 12 billion dollars)
Capitalization of 22 million euros, Cerenis ranks small capitalizations
Many round trips have been made on this security since the beginning of the year between 0.9 and 1.15 €, the positions bought around 0.35 € being kept.
Following rumors of interests around a patented molecule, the actions show a performance of 196.74% since the beginning of the year.
https://www.boursorama.com/cours/societe/profil/1rPABNX/
Medium-term objective around 2.5 € and 3 €
INNATE PHARMA: « Innate Pharma specializes in the research and development of innovative immunotherapy drugs for the treatment of cancer and inflammatory diseases. «
Following very good results on one of the main molecules in Innate Pharma’s portfolio, AstraZeneca entered 10% of the company’s capital at a price of € 10 per share when it was worth in November 2018 € 4.8 ,
It is now worth around € 5.6 [as of May 27, 2020], still below their purchase price.
As of January 29, 2019 « [BFM Bourse] – The candidate treatment for cutaneous lymphomas IPH4102 benefits from a potential boost from the American drug agency. Its commercialization could take place from 2023, bet a design office. The action benefits. «
What the specific status received by the US Food and Drug Administration means is that the molecule’s potential appears to be significant in the treatment of cancer and therefore that research and development must be accelerated.
Innate Pharma is starting trials on a treatment against COVID-19, which makes it, in addition to the other files in progress, an action with very high potential.
Average analyst consensus: € 12 by October 2020 [+ 105%]
The purpose of this article is only to present 3 companies which Capitelia believes are very interesting. No buying or selling advice is to be understood. The information presented here is the fruit of research and monitoring on these companies and of the thought of Capitelia. These values are preferred for informed investors.
Sources:
https://www.boursorama.com/cours/1rPONXEO/
